Summary
6.81 -0.01(-0.15%)07/05/2024
Mimedx Group Inc (MDXG)
Mimedx Group Inc (MDXG)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.15 | -1.73 | -7.97 | -2.85 | -12.69 | 5.75 | 56.55 | 110.14 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 6.81 | |
| Open | 6.82 | |
| High | 6.83 | |
| Low | 6.70 | |
| Volume | 378,315 | |
| Change | -0.01 | |
| Change % | -0.15 | |
| Avg Volume (20 Days) | 544,383 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 5.57 - 9.27 | |
| Price vs 52 Week High | -26.54% | |
| Price vs 52 Week Low | 22.26% | |
| Range | -0.15 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,002 | |
| EBIDTA | 7,711,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.9700 | |
| WallStreet Target Price | 13.83 | |
| Book Value | 0.1200 | |
| Earnings Per Share | -0.3200 | |
| EPS Estimate Current Quarter | -0.0800 | |
| EPS Estimate Next Quarter | -0.0700 | |
| EPS Estimate Current Year | -0.1800 | |
| EPS Estimate Next Year | -0.0300 | |
| Diluted EPS (TTM) | -0.3200 | |
| Revenues | ||
| Profit Marging | -0.1119 | |
| Operating Marging (TTM) | -0.0901 | |
| Return on asset (TTM) | -0.0743 | |
| Return on equity (TTM) | -0.3050 | |
| Revenue TTM | 259,754,000 | |
| Revenue per share TTM | 2.3680 | |
| Quarterly Revenue Growth (YOY) | -0.0190 | |
| Quarterly Earnings Growth (YOY) | 4.0000 | |
| Gross Profit (TTM) | 208,904,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 84.7293 | |
| Revenue Enterprise Value | 2.8452 | |
| EBITDA Enterprise Value | 117.9295 | |
| Shares | ||
| Shares Outstanding | 112,144,000 | |
| Shares Float | 71,674,857 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.76 | |
| Institutions (%) | 57.46 | |
07/01 14:18 EST - investorplace.com
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
06/26 16:01 EST - globenewswire.com
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.
05/15 08:00 EST - globenewswire.com
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
04/30 21:33 EST - seekingalpha.com
MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.
MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.
04/30 16:01 EST - globenewswire.com
MIMEDX Announces First Quarter 2024 Operating and Financial Results
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024.
MIMEDX Announces First Quarter 2024 Operating and Financial Results
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024.
04/16 08:00 EST - globenewswire.com
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
03/20 07:00 EST - globenewswire.com
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds
02/28 20:46 EST - seekingalpha.com
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
02/28 16:01 EST - globenewswire.com
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year
02/20 08:00 EST - globenewswire.com
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference.
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference.
02/13 12:58 EST - investorplace.com
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.
02/12 08:00 EST - globenewswire.com
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
01/30 19:35 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
01/22 08:00 EST - globenewswire.com
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities
01/19 21:30 EST - prnewswire.com
ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
NEW YORK , Jan. 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
NEW YORK , Jan. 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
01/17 11:04 EST - businesswire.com
MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
01/12 16:00 EST - businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your MiMedx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your MiMedx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.
01/12 13:24 EST - businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of federal securities laws. On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company's placental-derived tissue product, Axiofill, does not meet the requirements as a.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of federal securities laws. On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company's placental-derived tissue product, Axiofill, does not meet the requirements as a.